Discovery of highly potent triazole derivatives with broad-spectrum antifungal activity based on Iodiconazole

The widespread use of broad-spectrum Antibiotics, the growing number of immunocompromised individuals, and the emergence of drug-resistant strains have resulted in the increasing incidence and mortality of invasive Fungal infections. Azole drugs are the primary treatment for invasive Fungal infections, and Iodiconazole is a potent azole drug with strong Antifungal activity, but its stability is poor. In order to improve stability, a series of triazole compounds containing ethynyl group were designed and synthesized. Most of the compounds showed strong inhibitory activity against pathogenic fungi, among which compound 20l showed excellent inhibitory activity against pathogenic fungi and drug-resistant fungi. Importantly, and the stability of 20l (T_1/2 = 30.2 min) was obviously improved compared with Iodiconazole (T_1/2 = 4.39 min). In addition, the preferred compound 20l can prevent Fungal phase transition and the formation of Fungal biofilm, and show satisfactory fungicidal activity. In addition, the compound 20l was almost non-toxic to mammalian HUVEC cell and 293T cell. In vivo pharmacokinetic studies showed that 20l had acceptable pharmacokinetic properties. These results strongly demonstrate that compound 20l was worth further investigation as a potential Antifungal inhibitor.

Antifungal activity; CYP51 inhibitor; Drug-resistant; Stability; Triazole.